0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Iovance Biotherapeutics Inc

Healthcare US IOVA

11.54USD
-0.17(1.45%)

Last update at 2024-04-25T20:02:00Z

Day Range

11.1611.65
LowHigh

52 Week Range

3.219.36
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Minority interest - - - - -
Net income -389.92300M -327.82100M -257.22500M -187.07100M -123.58000M
Selling general administrative 104.10M 83.66M 60.21M 40.85M 28.43M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 21.14M 13.98M 1.14M 1.17M 0.96M
Ebit -420.01300M -356.68300M -261.93700M -208.04100M -129.21400M
Ebitda -398.87800M -342.70300M -260.79700M -206.87200M -128.25800M
Depreciation and amortization 21.14M 13.98M 1.14M 1.17M 0.96M
Non operating income net other - 0.45M 2.36M 9.32M 4.68M
Operating income -398.87800M -342.70300M -261.93700M -206.87200M -128.25800M
Other operating expenses 398.88M 342.70M 261.94M 206.87M 128.26M
Interest expense 2.98M 0.45M 2.36M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 2.98M 0.45M - 9.32M 4.68M
Net interest income 2.98M 0.45M 2.36M 9.32M 4.68M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -5.97000M -14.43100M -2.35600M -10.48500M 4.68M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 398.88M 342.70M 261.94M 206.87M 128.26M
Cost of revenue - - - - 0.00000M
Total other income expense net 2.98M 0.45M 2.36M 9.32M 4.68M
Discontinued operations - - - - -
Net income from continuing ops -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Net income applicable to common shares -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 663.98M 777.33M 768.46M 344.65M 480.82M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7.27M 3.55M 6.66M 9.41M 6.85M
Total liab 164.34M 155.67M 111.96M 45.68M 14.63M
Total stockholder equity 499.64M 621.66M 656.50M 298.97M 466.19M
Deferred long term liab - - - - 0.23M
Other current liab 52.30M 56.77M 35.07M 16.27M 11.66M
Common stock 0.00800M 0.00700M 0.00600M 0.00500M 0.00500M
Capital stock 0.01M 0.01000M 0.01000M 0.00900M 0.01M
Retained earnings -1568.33800M -1172.44500M -830.19300M -570.61200M -372.76000M
Other liab - - 11.71M 2.35M 0.23M
Good will - - - - -
Other assets 185.71M 777.33M 73.20M 8.93M 2.76M
Cash 231.73M 78.23M 67.33M 13.97M 82.15M
Cash and equivalents - - - - -
Total current liabilities 91.48M 89.20M 54.87M 39.08M 14.40M
Current deferred revenue - - - - -
Net debt -147.28500M -6.69800M -15.67000M -2.46900M -82.15200M
Short term debt 12.59M 5.06M 6.28M 7.25M -
Short long term debt - - - - -
Short long term debt total 84.45M 71.53M 51.66M 11.50M -
Other stockholder equity 2068.87M 1794.69M 1486.66M 869.35M 838.98M
Property plant equipment 178.25M 100.94M 59.16M 8.54M 2.68M
Total current assets 471.85M 507.96M 636.10M 312.53M 475.37M
Long term investments 0.00000M 91.59M - - -
Net tangible assets 499.63M 621.66M 656.49M 298.97M 466.19M
Short term investments 240.11M 426.18M 562.11M 293.11M 386.37M
Net receivables - - - - -
Long term debt 1.00M 1.00M - - -
Inventory - - - - -
Accounts payable 26.60M 27.38M 13.51M 15.57M 2.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.90200M -0.60100M 0.02M 0.22M -0.04200M
Additional paid in capital - - - - -
Common stock total equity - - 0.00600M 0.00500M 0.00500M
Preferred stock total equity - 0.00300M 0.00400M 0.00400M 0.00600M
Retained earnings total equity - -1172.44500M -830.19300M -570.61200M -372.76000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -171.81700M 7.87M 18.44M 12.89M 2.76M
Deferred long term asset charges - - - - -
Non current assets total 6.43M 269.38M 132.36M 32.12M 5.45M
Capital lease obligations 84.45M 70.53M 51.66M 11.50M -
Long term debt total - 1.00M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 256.45M 37.71M -271.06200M 96.94M -385.08100M
Change to liabilities 5.88M 27.66M 21.14M 19.43M 4.74M
Total cashflows from investing activities 256.45M 0.13M -317.85300M 90.03M -386.27900M
Net borrowings - 1.00M 1.00M 1.00M 1.00M
Total cash from financing activities 190.15M 239.27M 576.42M 6.13M 424.31M
Change to operating activities -8.77500M 17.58M 5.95M -2.69800M 1.16M
Net income -395.89300M -342.25200M -259.58100M -197.55600M -123.58000M
Change in cash 153.85M 11.46M 53.44M -62.73300M -63.22100M
Begin period cash flow 84.31M 72.85M 19.42M 82.15M 145.37M
End period cash flow 238.16M 84.31M 72.85M 19.42M 82.15M
Total cash from operating activities -292.75700M -227.94100M -205.13400M -158.88900M -101.24900M
Issuance of capital stock 189.50M 203.16M 567.04M - 398.82M
Depreciation 21.14M 13.98M 1.14M 1.17M 0.96M
Other cashflows from investing activities - - - 96.94M -385.08100M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 1.66M 1.59M 576.71M 6.44M 424.53M
Other cashflows from financing activities -1.00700M 34.53M 9.38M 6.13M 25.49M
Change to netincome 84.89M 69.77M 40.89M 23.96M 20.04M
Capital expenditures 20.43M 37.57M 46.79M 6.92M 1.20M
Change receivables - - - - -
Cash flows other operating - 7.76M -10.59000M -2.47200M -2.06500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - 11.46M 53.44M -62.73300M -63.22100M
Change in working capital -2.89200M 24.55M 2.98M 10.01M 2.67M
Stock based compensation 84.02M 69.77M 40.89M 24.28M 20.03M
Other non cash items 0.87M 6.01M 7.57M 6.62M -1.32300M
Free cash flow -313.18200M -265.51500M -251.92500M -165.80600M -102.44700M

Fundamentals

  • Previous Close 11.71
  • Market Cap1837.49M
  • Volume3373204
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-434.61699M
  • Revenue TTM0.71M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.08

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IOVA
Iovance Biotherapeutics Inc		 -0.17 1.45% 11.54 - - 2830.66 2.98 2442.81 -4.1395
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics Inc

825 Industrial Road, San Carlos, CA, United States, 94070

Key Executives

Name Title Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, Pres, Gen. Counsel & Corp. Sec. 1974
Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer 1972
Dr. Igor P. Bilinsky Chief Operating Officer 1973
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 1967
Ms. Sara Pellegrino VP of Investor Relations & PR NA
Ms. Tracy Winton Sr. VP of HR NA
Mr. Howard B. Johnson M.B.A. Chief Bus. Officer 1960
Mr. James Ziegler M.B.A. Exec. VP of Commercial NA
Mr. Madan Jagasia Exec. VP of Medical Affairs NA
Dr. Raj K. Puri M.D., Ph.D. Exec. VP of Regulatory Strategy & Translational Medicine NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).